Tumor-induced osteomalacia (TIO) is a rare acquired paraneoplastic syndrome characterized by abnormal phosphate and vitamin D metabolism caused by small endocrine tumors called phosphaturic mesenchymal tumors (PMTs).

Patients can develop the disease at any age. However, the average duration from onset of symptoms to diagnosis is approximately 5 years. Most cases are diagnosed between 40-50 years of age.
BACKGROUND – PATHOPHYSIOLOGY

Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterized clinically by tumoral production of fibroblast growth factor 23 (FGF23), muscle weakness, fatigue, musculoskeletal pain, and fractures.

FGF23 is produced by a number of tissues including osteoblasts and osteocytes. FGF23 is a hormone which regulates phosphate metabolism. In binding to renal FGF receptor 1 and co-receptor α-Klotho complex, FGF23 inhibits sodium phosphate co-transporters (NaPi-IIa, NaPi-IIc), resulting in reduced renal phosphate reabsorption. In addition, FGF23 blocks the conversion of 25-hydroxyvitamin D to its active form 1,25-dihydroxyvitamin D (1,25(OH)₂D), leading to decreased phosphate absorption from the intestine.

In TIO, the uncontrolled increased FGF23 production is typically caused by small, slow growing, benign phosphaturic mesenchymal tumors (PMTs) that may be localized to almost any part of the body that has either bone or connective tissue. Thus, TIO is characterized by defective bone mineralization (osteomalacia in adults, or rickets in children) due to high phosphatonin levels.

PMT TUMORIGENESIS: FN1-FGFR1 AND FN1-FGF1 TRANSLOCATIONS ELEVATED α-KLOTHO EXPRESSION

A key pathogenic mechanism of TIO is the uncontrolled tumoral production of FGF23. Recently, certain fusion genes have been identified in a subset of PMTs. The most common fusion gene is the FN1-FGFR1 (FN1 encoding fibronectin, FGFR1 encoding fibroblast growth factor receptor 1). A rarer fusion gene, FN1-FGF1 has also been identified. In both known fusions, it is likely that fibronectin stimulates overexpression of the fusion gene product. In the fusion negative PMTs, α-Klotho, an obligatory co-receptor for FGFR1, is often over expressed. In both situations, increased FGFR1 signaling is the end result with PMT tumorigenesis and/or FGF23 hypersecretion.

Mineralization of bone matrix: normal bone (left) and osteomalacia (right)
Fusaro M, et al., Nutrients 2022
**DIAGNOSIS**

TIO is challenging to diagnose as the manifestations are non-specific, often leading to a delayed diagnosis. Moreover, patients are frequently misdiagnosed with several other common rheumatologic, neurological, psychiatric conditions including osteoporosis, somatic syndrome, intervertebral disc herniation, etc. Patients presenting with FGF23-mediated hypophosphatemia require a thorough clinical and laboratory evaluation to distinguish TIO from other genetic and acquired causes of FGF23 excess.

### Key elements that guide diagnosis:
- Unexplained low serum phosphate
- Age of onset of symptoms
- Absence of family history of rickets/osteomalacia
- Muscle weakness (usually more proximal than distal)

### Clinical presentation

**Symptoms of chronic hypophosphatemia**
- Bone pain
- Difficulty in walking
- Muscle weakness
- Pathological multiple fractures (mainly long bones)
- Pseudofractures

### Laboratory Analysis

<table>
<thead>
<tr>
<th>Serum values</th>
<th>Urine values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low phosphate*</td>
<td>Elevated or inappropriately normal phosphate**</td>
</tr>
<tr>
<td>Elevated or inappropriately normal intact FGF23*</td>
<td>Reduced TmP/GFR***</td>
</tr>
<tr>
<td>Low or inappropriately normal 1,25(OH)(_2)D(_3)</td>
<td></td>
</tr>
<tr>
<td>Elevated bone alkaline phosphatase</td>
<td></td>
</tr>
<tr>
<td>Normal calcium (typically normal in TIO)</td>
<td></td>
</tr>
<tr>
<td>Intact PTH may be high due to chronically low 1,25(OH)(_2)D(_3)</td>
<td></td>
</tr>
<tr>
<td>Normal 25(OH) vitamin D</td>
<td></td>
</tr>
</tbody>
</table>

TmP/GFR: tubular maximal reabsorption of phosphate adjusted for glomerular filtration rate
*Fasting before sampling is required to give an accurate result
** Second morning void urine or urine collected over 24 hours
*** TmP/GFR is calculated from fasting paired plasma and second morning void urine samples obtained 2 hours after the first void urine for phosphate and creatinine

### TUMOR LOCALIZATION

After establishing the diagnosis of TIO, the next step in management is identification of lesion (or lesions).

#### Functional imaging

**Recommended modalities to localize metabolic active PMT cells**
- Somatostatin receptor scintigraphy (SRS)
  - \(^{68}\)Gallium DOTA-Phe\(^1\)-Tyr\(^3\)-Thr\(^8\)octreotide (\(^{68}\)Ga-DOTATATE) PET/CT
  - \(^{111}\)Indium-labeled pentetrotide (OctreoScan\(^{TM}\)) SPECT/CT
- Glucose transporter imaging
  - \(^{18}\)F fluorodeoxyglucose (\(^{18}\)F-FDG) PET/CT

#### Anatomical imaging

Of the suspicious areas to confirm the specific location of the tumor and its surrounding tissues to assist surgical planning
- Contrast-enhanced CT
- Resonance imaging (MRI)
**Densitometry in TIO**
Although it is commonly used in the bone density assessment, dual-energy X-ray absorptiometry (DXA) does not exclude nonmineralized bone. Therefore, this is not a good measure of bone mass in patients with osteomalacia. On the other hand, it can be safely and reliably used to monitor mineralization of the osteoid during treatment and serves as an important measure of bone disease healing.

**Body biopsy in TIO**
Bone biopsy is helpful for assessing the severity of bone disease in TIO. However, this is impractical and seldom necessary for a diagnosis of TIO.

---

**TREATMENT**

- **Complete tumor resection**
- **Ablative procedures**
  - External beam radiation, image-guided ablation with radiofrequency, cryoablation
- **Conventional medical treatment**
  - Oral phosphate supplementation in combination with active vitamin D analogs
  - Human monoclonal antibody against FGF23 (burosumab)
  - Burosumab (CRYSVITA®) is a recombinant human monoclonal antibody against FGF23. As of June 2022, burosumab is approved in the USA for the treatment of FGF23-related hypophosphatemia in TIO associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localized, in adult and pediatric patients aged 2 years and older.

**ALGORITHM OF IDENTIFICATION AND TREATMENT FOR TUMOR-INDUCED OSTEOMALACIA**

1. Hypophosphatemia
2. Medical/family history
3. Clinical examination
4. Laboratory evaluation
5. Functional imaging
6. Lesion localized
   - Anatomical imaging
   - Resectable
     - Surgical resection
   - Unresectable
     - Ablative procedures
8. Lesion not localized
   - Medical therapy
   - Repeat functional imaging after a few years
9. Medical therapy

---

**References:**
5. Florenzano P, et al. Tumor-Induced Osteomalacia, Calcif Tissue Int. 2021

**Authoried by the IOF Skeletal Rare Disease Academy**
Prof. N Harvey, Prof. ML Brandi, Dr. M Chandran, Prof. R Chapurlat, Prof. S Ferrari, Assoc. Prof. K Javaid

**Financially supported by Kyowa Kirin, which had no input into the content or choice of author for the factsheet.**